This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hemming, V. G. Articles by Siber, G. R. Search for Related Content PubMed PubMed Citation Articles by Hemming, V. G. Articles by Siber, G. R.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, Jan 1995, 22-33, Vol 8, No. 1
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections

VG Hemming, GA Prince, JR Groothuis and GR Siber
Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814.

Respiratory syncytial virus (RSV) is an important community and nosocomial respiratory pathogen for infants and young children. RSV causes especially severe disease in the prematurely born or those with chronic cardiopulmonary diseases. Elderly persons and those with T-cell deficiencies, such as bone marrow transplant recipients, are also at high risk for serious lower respiratory tract infections. To date, prevention of RSV infections by vaccination has proven elusive and no preventive drugs exist. Studies in animals and humans have shown that the lower respiratory tract can be protected from RSV infection by sufficient circulating RSV neutralizing antibody levels. Recently, an RSV hyperimmune immune globulin (RSVIG) was developed and tested for the prevention of RSV infections or reduction of disease severity. Passive immunization of high-risk children with RSVIG during the respiratory disease season effected significant reductions in RSV infections, hospitalizations, days of hospitalization, intensive care unit admissions, days in the intensive care unit, and ribavirin use. Studies in cotton rats and owl monkeys show that RSV infections can also be treated with inhalation of immune globulin at doses substantially smaller than required for parenteral treatment. Therapeutic trials of parenteral RSVIG have been completed and are pending analysis. The use of polyclonal, hyperimmune globulins and perhaps human monoclonal antibodies provides an additional approach to the prevention and perhaps the treatment of certain viral lower respiratory tract infections such as those caused by RSV.

This article has been cited by other articles:

• Pueschel, K., Tietz, A., Carsillo, M., Steward, M., Niewiesk, S. (2007). Measles Virus-Specific CD4 T-Cell Activity Does Not Correlate with Protection against Lung Infection or Viral Clearance. J. Virol. 81: 8571-8578 [Abstract] [Full Text]  
• Williams, J. V., Chen, Z., Cseke, G., Wright, D. W., Keefer, C. J., Tollefson, S. J., Hessell, A., Podsiad, A., Shepherd, B. E., Sanna, P. P., Burton, D. R., Crowe, J. E. Jr., Williamson, R. A. (2007). A Recombinant Human Monoclonal Antibody to Human Metapneumovirus Fusion Protein That Neutralizes Virus In Vitro and Is Effective Therapeutically In Vivo. J. Virol. 81: 8315-8324 [Abstract] [Full Text]  
• Singleton, R., Etchart, N., Hou, S., Hyland, L. (2003). Inability To Evoke a Long-Lasting Protective Immune Response to Respiratory Syncytial Virus Infection in Mice Correlates with Ineffective Nasal Antibody Responses. J. Virol. 77: 11303-11311 [Abstract] [Full Text]  
• Hemming, V. G. (2001). Use of Intravenous Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases. CVI 8: 859-863 [Full Text]  
• Snell, N. J. C. (2001). New treatments for viral respiratory tract infections--opportunities and problems. J Antimicrob Chemother 47: 251-259 [Full Text]  
• Tripp, R. A., Jones, L., Anderson, L. J., Brown, M. P. (2000). CD40 Ligand (CD154) Enhances the Th1 and Antibody Responses to Respiratory Syncytial Virus in the BALB/c Mouse. J. Immunol. 164: 5913-5921 [Abstract] [Full Text]  
• Weltzin, R., Monath, T. P. (1999). Intranasal Antibody Prophylaxis for Protection against Viral Disease. Clin. Microbiol. Rev. 12: 383-393 [Abstract] [Full Text]  
• Domachowske, J. B., Rosenberg, H. F. (1999). Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis, and Treatment. Clin. Microbiol. Rev. 12: 298-309 [Abstract] [Full Text]  
• Dudas, R. A., Karron, R. A. (1998). Respiratory Syncytial Virus Vaccines. Clin. Microbiol. Rev. 11: 430-439 [Abstract] [Full Text]  
• Kreil, T. R., Maier, E., Fraiss, S., Eibl, M. M. (1998). Neutralizing Antibodies Protect against Lethal Flavivirus Challenge but Allow for the Development of Active Humoral Immunity to a Nonstructural Virus Protein. J. Virol. 72: 3076-3081 [Abstract] [Full Text]  
• Nachman, S. A., Navaie-Waliser, M., Qureshi, M. Z. (1997). Rehospitalization With Respiratory Syncytial Virus After Neonatal Intensive Care Unit Discharge: A 3-Year Follow-up. Pediatrics 100: e8-e8 [Abstract] [Full Text]  
• Meissner, H. C., Groothuis, J. R. (1997). Immunoprophylaxis and the Control of RSV Disease. Pediatrics 100: 260-260 [Full Text]  
• Committee on Infectious Diseases, , Committee on Fetus and Newborn, (1997). Respiratory Syncytial Virus Immune Globulin Intravenous: Indications for Use. Pediatrics 99: 645-650 [Abstract] [Full Text]  
• Russell, B., Prober, C. G., Wang, E. E. L. (1997). Reducing the Morbidity of Lower Respiratory Tract Infections Caused by Respiratory Syncytial Virus: Still No Answer. Pediatrics 99: 472-472 [Full Text]